Appointment aligns Board leadership with Company’s transition to clinical-stage development and advancement of KAD-101 for platinum-resistant ...

New OHSU study maps antibody "hot spots" behind anti‑NMDAR encephalitis. Could change diagnosis and treatment.

A new OHSU study shows how the immune system can quietly disrupt brain function — and why the disease is often hard to ...

Psychedelics, psychoactive substances that alter people's perceptions, mood and thought patterns, have recently shown promise ...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and ...

Alcohol use is widespread and alcohol use disorder (AUD) causes substantial harm. AUD affects 29 million individuals and ...

A TRPV1 antagonist is well tolerated and can improve dry eye disease symptoms and clinical signs as early as week 1, a Phase 2b study shows.

- ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 ...

AM-710 is an ultra-long-acting prodrug of orforglipron, with >150-fold half-life extension, enabling once every 3 month and once every 6 month dosing or longer A single subcutaneous dose of AM-710 ...

Background: Multiple glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer dual/triple co-agonists promote weight loss in adults without diabetes, yet comparative efficacy across agents ...